Logo wahanariau.com
  2. Adagene

Adagene

Index
Globenewswire

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Rabu, 17 Desember 2025 - 07:01:21 Wib
Globenewswire

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Kamis, 13 November 2025 - 23:24:02 Wib
Globenewswire

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Sabtu, 01 November 2025 - 01:03:57 Wib
Globenewswire

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Selasa, 16 September 2025 - 19:30:00 Wib
Globenewswire

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Jumat, 05 September 2025 - 20:47:22 Wib
Globenewswire

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Rabu, 03 September 2025 - 23:38:04 Wib
Globenewswire

Adagene to Participate in Two Investor Conferences in September

Selasa, 26 Agustus 2025 - 23:06:44 Wib
Globenewswire

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Rabu, 13 Agustus 2025 - 19:55:00 Wib
Globenewswire

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Rabu, 16 Juli 2025 - 01:27:26 Wib
Globenewswire

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Selasa, 08 Juli 2025 - 21:59:29 Wib
Globenewswire

Adagene Announces up to $25 Million Strategic Investment from Sanofi

Selasa, 01 Juli 2025 - 18:30:00 Wib
Globenewswire

Adagene to Present at Jefferies Global Healthcare Conference 2025

Selasa, 27 Mei 2025 - 19:00:00 Wib
Globenewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jumat, 23 Mei 2025 - 21:30:35 Wib
Globenewswire

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Selasa, 29 April 2025 - 03:05:45 Wib
Globenewswire

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Rabu, 23 April 2025 - 21:22:05 Wib
Globenewswire

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

Selasa, 08 April 2025 - 04:04:38 Wib
Globenewswire

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

Senin, 24 Maret 2025 - 23:03:08 Wib
Globenewswire

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

Kamis, 13 Maret 2025 - 19:30:00 Wib
Globenewswire

Adagene to Present at Leerink’s Global Healthcare Conference 2025

Kamis, 06 Maret 2025 - 20:30:00 Wib
Globenewswire

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

Jumat, 28 Februari 2025 - 00:20:02 Wib
Globenewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Senin, 27 Januari 2025 - 19:30:00 Wib
Globenewswire

Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium

Rabu, 22 Januari 2025 - 14:35:27 Wib
Globenewswire

Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025

Selasa, 14 Januari 2025 - 20:30:00 Wib
Globenewswire

Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Soc

Kamis, 07 November 2024 - 22:30:00 Wib
Globenewswire

Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Rabu, 09 Oktober 2024 - 17:30:00 Wib